Department of Vascular Surgery, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang, China.
Department of Urology, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang, China.
Endocr Metab Immune Disord Drug Targets. 2024;24(8):918-929. doi: 10.2174/0118715303251692231112150225.
Macrovascular lesions are the main cause of death and disability in diabetes mellitus, and excessive accumulation of cholesterol and lipids can lead to long-term and repeated damage of vascular endothelial cells. Umbilical cord mesenchymal stem cells (UCMSCs) can attenuate vascular endothelial damage in type 1 diabetic mice, while Fufang Xueshuantong capsule (FXC) has a protective effect on endothelial function; however, whether FXC in combination with UCMSCs can improve T2DM macrovascular lesions as well as its mechanism of action are not clear. Therefore, the aim of this study was to reveal the role of FXC + UCMSCs in T2DM vasculopathy and their potential mechanism in the treatment of T2DM.
The control and T2DM groups were intragastrically administered with equal amounts of saline, the UCMSCs group was injected with UCMSCs (1×10, resuspended cells with 0.5 mL PBS) in the tail vein, the FXC group was intragastrically administered with 0.58 g/kg FXC, and the UCMSCs + FXC group was injected with UCMSCs (1×10) in the tail vein, followed by FXC (0.58 g/kg), for 8 weeks.
We found that FXC+UCMSCs effectively reduced lipid levels (TG, TC, and LDL-C) and ameliorated aortic lesions in T2DM rats. Meanwhile, Nrf2 and HO-1 expression were upregulated. We demonstrated that inhibition of Nrf-2 expression blocked the inhibitory effect of FXC+UCMSCs-CM on apoptosis and oxidative stress injury.
Our data suggest that FXC+UCMSCs may attenuate oxidative stress injury and macroangiopathy in T2DM by activating the Nrf-2/HO-1 pathway.
大血管病变是糖尿病死亡和残疾的主要原因,胆固醇和脂质的过度积累可导致血管内皮细胞的长期和反复损伤。脐带间充质干细胞(UCMSCs)可减轻 1 型糖尿病小鼠的血管内皮损伤,而复方血栓通胶囊(FXC)对内皮功能具有保护作用;然而,FXC 联合 UCMSCs 是否能改善 T2DM 大血管病变及其作用机制尚不清楚。因此,本研究旨在揭示 FXC+UCMSCs 在 T2DM 血管病变中的作用及其在 T2DM 治疗中的潜在机制。
对照组和 T2DM 组给予等体积生理盐水,UCMSCs 组尾静脉注射 UCMSCs(1×10 个,用 0.5 mL PBS 悬浮细胞),FXC 组灌胃给予 0.58 g/kg FXC,UCMSCs+FXC 组尾静脉注射 UCMSCs(1×10 个),然后给予 FXC(0.58 g/kg),共 8 周。
我们发现 FXC+UCMSCs 可有效降低 T2DM 大鼠的血脂水平(TG、TC 和 LDL-C),改善主动脉病变。同时,Nrf2 和 HO-1 的表达上调。我们证明抑制 Nrf-2 表达可阻断 FXC+UCMSCs-CM 对细胞凋亡和氧化应激损伤的抑制作用。
我们的数据表明,FXC+UCMSCs 通过激活 Nrf-2/HO-1 通路可能减轻 T2DM 中的氧化应激损伤和大血管病变。